SGC707 50 mg | Purity Not Available
TargetMol
SGC707 is a potent, selective, and cell-active allosteric inhibitor of PRMT3.
More Information Supplier PageSGC707
Search Results
PS-1145 10 mg | 97.06%
TargetMol
PS-1145
SC66 50 mg | 99.60%
TargetMol
SC66 is a AKT inhibitor in HepG2, HA22T/VGH, and PLC/PRF/5 cells (IC50: about 0.75 μg/ml, at 72 h).
More Information Supplier PageSC66
SC66 25 mg | 99.60%
TargetMol
SC66 is a AKT inhibitor in HepG2, HA22T/VGH, and PLC/PRF/5 cells (IC50: about 0.75 μg/ml, at 72 h).
More Information Supplier PageSC66
SC66 10 mg | 99.60%
TargetMol
SC66 is a AKT inhibitor in HepG2, HA22T/VGH, and PLC/PRF/5 cells (IC50: about 0.75 μg/ml, at 72 h).
More Information Supplier PageSC66
PS-1145 5 mg | 97.06%
TargetMol
PS-1145
PS-1145 50 mg | 97.06%
TargetMol
PS-1145
PS-1145 25 mg | 97.06%
TargetMol
PS-1145
Regadenoson 25 mg | 99.57%
TargetMol
Regadenoson is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher […]
More Information Supplier PageRegadenoson
Regadenoson 2 mg | 99.57%
TargetMol
Regadenoson is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher […]
More Information Supplier PageRegadenoson